

Innovation

in health for the

World



A circular inset image on the left side of the slide shows a close-up of a scientist wearing safety goggles and a white lab coat, holding a small glass vial. The background of the entire slide is a dark blue gradient with abstract white and light blue geometric shapes and patterns, including a DNA helix and circuit-like lines.

Innovation, Science, and Technology for the World

Blaū Farmacêutica é

is a regional company with a strong presence across Latin America, a leader in the hospital pharmaceutical segment* and a pioneer in biotechnology in Brazil.

We are a publicly traded company listed on the Brazilian Stock Exchange (B3) under the ticker “Blau3.” Our commitment is to deliver innovative specialty medicines that ensure efficacy, safety, and quality, providing patients with the best therapeutic options, as determined by their medical teams and/or healthcare professionals.

*Source: IQVIA 2025.

ABOUT US

With a broad portfolio of proprietary specialty medicines, we operate in key therapeutic areas such as immunology, hematology, oncology, nephrology, infectious diseases, anesthesiology, and others.

We are structured into three business units: Onco-Hemato & Specialties, Pharma/Retail, and Aesthetics, each with its own commercial and marketing teams, as well as independent financial management.

Regional operations with a global presence



Blaū's presence
in the global
pharmaceutical
market

**Over 2,500
employees**
across the Americas.

**5 production
plants + API
plant**

**Modern industrial
structure** with high
production capacity and
cutting-edge
technology.

**Broad national
and international
coverage**, meeting
the needs of several
markets.

**Continuous
investment** in
research and
development, driving
innovation.

WHERE WE ARE

Our presence extends throughout Latin America, including Argentina, Chile, Colombia, Ecuador, Mexico, Peru, and Uruguay, and to the United States through Hemarus (our plasma collection centers), with proprietary medicines marketed globally.

We operate five pharmaceutical manufacturing plants in Brazil and one API (Active Pharmaceutical Ingredient) plant, all equipped with cutting-edge technology and integrated monitoring and control systems that meet the strictest international Good Manufacturing Practices (GMP) standards.

Five production units in Brazil and one in Uruguay.

Cotia - Brazil



São Paulo - Brazil



Blau - Bergamo - Brazil



Goiás - Brazil



Caucaia - Brazil



Uruguay



Our production processes are guided by **Industry 4.0 principles**, thereby ensuring high productivity, operational efficiency, and full digitalization of production order issuance and control.



Over 35 years of innovation and technology.



Pioneer in the development of biotechnological medicines in Brazil.



Regional operations with a **strong presence across Latin America.**



Nationwide operations, in both private and public channels, and through distribution with our own team.



Exporting to over **20 countries.**

Leadership And Innovation

Blaü Plant - Cotia



Brazilian company

leader in the institutional/non-retail segment.*



1.7 billion Brazilian Reais

(Net revenue in 2025).



Largest portfolio

in the Brazilian onco-hematology market.*



+100 molecules

Broad portfolio of proprietary specialty medicines.



Over 9,000 institutions in the hospital market*

6,500+ hospitals/clinics

1,700+ public agencies

400+ oncology clinics

300+ nephrology centers



Presence in 70% of the Pharma/Retail market

in over 68,000 pharmacies throughout Brazil.*

A background image showing laboratory glassware, specifically test tubes in a rack, with numbers 3, 4, 5, and 6 visible on the black caps. The image is partially obscured by a blue geometric overlay.

Our Purpose

To develop and provide innovative products and solutions for a healthier and more sustainable world.

Our Vision

- To be the leading Brazilian company in sales in the institutional market in Latin America.
- To increase participation in other healthcare markets.
- To expand the vertical integration of operations.

Our Values

- Integrity
- Quality
- Efficacy
- Team spirit
- Boldness

Our History

A journey marked by growth and success



Sustainable and consistent growth over the years.



Continuous investments in various growth pillars.



Strategic vision and focus on internationalization



1987

Blaüsiegel is founded

1995

Oncology drug manufacturing facility established in Blaü Caucaia do Alto (SP)

2005

Approval to manufacture biologic medicines at the - Blaü Cotia (SP) P200 and P300 plants

2012

Antibiotics manufacturing begins at the - Blaü São Paulo (SP) plant

1992

Begins importing specialty medicines.

2001

Opening of the Blaü Cotia (SP) industrial complex - headquarters

2011

Corporate brand updated to Blaü Farmacêutica

2014

Start of Blaü Uruguay operations

Our History

A journey marked by growth and success



Products and Solutions

3 business units

Excellence in each area of operation

- Comprehensive approach that meets the different demands of the pharmaceutical market.
- Expertise in each area, ensuring high-quality and effective products.
- Focus on innovation and solution development.



Onco-Hemato & Specialties

- Robust oncology portfolio.
- Our medicines help minimize the main side effects of cancer treatments, including antiemetics, white blood cell stimulants, and mucositis protectors, among others.
- Specialty medicines for hospital use.
- We offer a comprehensive portfolio of specialty medicines for hospital care, supporting patients from their initial admission through emergency departments to specialized care units, including ICUs, operating rooms, and inpatient settings.
- Our portfolio includes a wide range of injectable antibiotics, antivirals, anticoagulants, plasma-derived therapies, muscle relaxants, analgesics, anesthetics, and other essential hospital medicines.



Pharma/Retail

- Prescription and consumer healthcare products for a wide range of therapeutic indications, particularly chronic conditions such as rheumatoid arthritis and anemia, as well as oral oncology, nephrology, hematology, gynecology, gastroenterology, infectious diseases, anticoagulation therapies, topical gels, a complete line of male condoms, and many other products available through the retail channel.
- Our portfolio includes both prescription medicines and over-the-counter (OTC) products.



Blaū Aesthetics

- Innovative solutions for aesthetic procedures, including hyaluronic acid dermal fillers and injectable products.
- We provide a portfolio of minimally invasive aesthetic treatment solutions designed to meet or exceed the expectations of healthcare professionals specializing in aesthetic medicine.



A photograph of a scientist in a white lab coat, blue hairnet, and white face mask, looking through a microscope. Another scientist is visible in the background, also in a lab coat and mask.

Blaū Farmacêutica Research, Development, and Innovation Center

Our **Research & Development Center** is equipped with cutting-edge technology and dedicated pilot plants for injectable products and solid oncology medicines, operating in accordance with stringent development practices and regulatory compliance standards.

We have a team of over **200 professionals**, comprising **scientists, clinical researchers, PhDs, and other highly qualified specialists**.

In 2025, we invested approximately 11% of our annual net revenue (BRL 188 million) in Research, Development & Innovation (RD&I), underscoring our ongoing commitment to advancing pharmaceutical innovation and scientific discovery.

API

Vertical integration and technological independence.

We invest in the production of **Active Pharmaceutical Ingredients (APIs)** to support the development of proprietary products and strengthen supply chain self-sufficiency.

In Brazil, we are among the few companies with the capabilities to develop the entire biopharmaceutical value chain, from the research and manufacture of APIs to the production of the finished drug product.

Manufacturing units:

Cotia/SP: 2 plants with cutting-edge technology.

Over 3,000 m² of total area

- Greater quality control at all stages of production.

- Reduced dependence on the international market.

- More agility in developing new products.

- Greater security and predictability in the supply of inputs.



ESG:

Commitment to Sustainability

For Blaū, **Innovation and ESG are inseparable pillars** that reflect our commitment to governance, technology, and efficiency in production, as well as environmental and social responsibility.

We are the **first pharmaceutical company in the sector*** to be affiliated with the **Zero Waste Certification**.

Blaū's Annual Sustainability Report follows **Global Reporting Initiative (GRI) standards**, showcasing ongoing improvements and measurable results across multiple areas of corporate management.

*Source: Zero Waste .

Corporate Governance

We maintain robust and transparent governance controls and processes, as well as compliance guidelines that ensure ethics and responsibility in our decisions.

Environmental Management

We invest in more eco-efficient production processes, continuously working to reduce natural resource consumption, waste generation, and greenhouse gas emissions.

Social Management

We are dedicated to the well-being of our employees and the communities surrounding our operations, investing in social projects that positively impact education, culture, and quality of life, bringing hope and inclusion to people's lives.





**Blaū – Escritório Administrativo Cidade
Jardim Corporate**

Av. Magalhães de Castro, 4800 Torre
Continental, 21º andar Jardim Panorama,
São Paulo/SP – CEP 05676-120

Tel.: 55 (11) 4615 9400 • sac@blau.com.br



Scan the QR
code to visit
our website:



[/blaufarmaceutica](https://www.facebook.com/blaufarmaceutica)



[@blaufarmaceutica](https://www.instagram.com/blaufarmaceutica)



[blaufarmaceutica](https://www.linkedin.com/company/blaufarmaceutica)